FDA Advisory Committee Recommends Pfizer Vaccine for Kids — Is It Worth an Investment Ahead of Approval?

Children getting COVID vaccine before schools open concept stock photo
Grandbrothers / iStock.com

The U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted to recommend the FDA grant Emergency Use Authorization (EUA) for Pfizer’s COVID-19 vaccine in children 5 to 11 yesterday.

See: 8 Best Cryptocurrencies To Invest In for 2021
Find: Shiba Inu Whale Purchase Sends Crypto to New Highs, But Should You Buy?

The news didn’t help the stock price, however, which was down 1.8% this morning.

The FDA is expected to make its decision in the coming days. If authorized and subsequently recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), the Pfizer-BioNTech COVID-19 Vaccine will be the first COVID-19 vaccine available for use in children 5 to 11 in the U.S., Pfizer said in an announcement.

Pfizer also announced that it expects to begin shipping pediatric vaccine doses immediately upon approval, as directed by the U.S. government.

More: WHO Touts New Malaria Vaccine as ‘Historic’ — Is It Worth an Investment?

Keith Speights, a contributing Motley Fool analyst, told GOBankingRates that the FDA advisory committee’s vote wasn’t surprising, and while the FDA doesn’t have to go along with the committee’s recommendation, it’s highly likely to do so.

“What might be surprising to investors, though, is that Pfizer stock didn’t rise on the news and actually slipped a little in early trading on Wednesday,” Speights said. “The reason why is that the U.S. government has already bought more than enough doses of the Pfizer-BioNTech vaccine to give to all children ages five to 11 and still meet the demand in other age groups. While the increased likelihood of authorization of the vaccine for younger kids is good news for Pfizer, it won’t have any near-term financial impact on the company,” he added.

Building Wealth

Explore: Moderna Chairman Refuses To Share Vaccine Formula — Will Pfizer’s Popularity Hurt Its Stock Value?
Learn: With Two-Thirds of US Workforce Under Vaccine Mandate Soon, Concern Mounts Over Employee Retention

Pfizer will report its third quarter earnings on November 2, and the Zacks consensus estimate for vaccine products is $14.51 billion, respectively.

More From GOBankingRates

Last updated: October 27, 2021

About the Author

Yaël Bizouati-Kennedy is a full-time financial journalist and has written for several publications, including Dow Jones, The Financial Times Group, Bloomberg and Business Insider. She also worked as a vice president/senior content writer for major NYC-based financial companies, including New York Life and MSCI. Yaël is now freelancing and most recently, she co-authored  the book “Blockchain for Medical Research: Accelerating Trust in Healthcare,” with Dr. Sean Manion. (CRC Press, April 2020) She holds two master’s degrees, including one in Journalism from New York University and one in Russian Studies from Université Toulouse-Jean Jaurès, France.

Best Bank Accounts of June 2022

Untitled design (1)
Close popup The GBR Closer icon

Sending you timely financial stories that you can bank on.

Sign up for our daily newsletter for the latest financial news and trending topics.

Please enter an email.
Please enter a valid email address.
There was an unknown error. Please try again later.

For our full Privacy Policy, click here.